Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Heplisav Postmarketing Worries Push PDUFA Date Back; FDA Seeks More Details

04 Aug 2017

• By Michael Cipriano

Hepatitis B

Related Content

Heplisav Vaccine Postmarketing Study Might Overcome FDA Safety Worries At Panel

26 Jul 2017

Heplisav Seems Headed For Approval, But With More Robust Postmarketing Study

30 Jul 2017

Related Companies

Dynavax Technologies Corporation

GSK plc

Additional Topics

United States Advisory Committees Vaccines Post Market Regulation & Studies Drug Safety Regulation BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.